Daily Financial Update
Opening Recap
Market Pulse: Tech names dip dragged the S&P slightly into negative territory as big pharma jitters rattled the weight-loss arena.
Key Movers: Novo Nordisk, Vanda and Mesoblast dominated trading—each story spotlighted regulatory inflection points from anti-obesity pills to motion-sickness approvals and boardroom reshuffles.
Macro & Politics: A fresh lunar push from former President Trump reminds us that space policy can move markets—defense and satellite plays are sitting on a potential runway.
What’s Next: Track this week’s FDA calendar—any unexpected green lights or delays will spark knee-jerk moves in biotechs.
📈 Breaking Financial News
Silver Mania Begins
This post Silver Mania Begins appeared first on Daily Reckoning.
I love the smell of a short squeeze in the morning…
The post Silver Mania Begins appeared first on Daily Reckoning.
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market
The FDA approval of the Wegovy pill highlights many of the key themes Novo Nordisk will have to face in 2026.
Vanda jumps 18% to $8.33 after motion sickness FDA approval
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Trip Your Way to Better Health? Researchers See Medical Potential in Ketamine, Mushrooms and Ibogaine | High Times
The PhilaDelic’s Fall Forum sets a roadmap for wider use of ibogaine and mushrooms to treat addiction and depression as stigma fades. Leading chemists, psychiatrists, treatment pros, academics and activists gather to widen use of psychedelic drugs.
Mesoblast Announces Changes to Board of Directors' Leadership Roles
NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake …
White House Insider Buck Sexton: “Trump's Next Move Will Shock the World” It cou
dramatically increase U.S. power… and trigger a massive American market boom the likes of which we haven't seen in 75 years. Get the details here now.
🔍 Market Analysis & Insights
Best ACV Gummies 2026 Report: True Keto Fusion Analyzed in New Year Keto-ACV Industry Analysis
Industry analysis examines best ACV gummies for 2026, featuring True Keto Fusion as keto-ACV hybrid formulations gain consumer search interest….
Big changes coming for weight loss drugs in 2026: Pills, price changes and more
Long-defined by high prices, shortages and weekly injections, weight loss drugs including Wegovy and Zepbound are expected to be easier to access and afford.
Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)’s Weight Loss Pill
We recently published 10 Stocks on Jim Cramer’s Radar. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer’s radar. Danish pharmaceutical firm…
Michael Saylor’s MicroStrategy plunges on New Year’s Eve
If one thing we have learned about Michael Saylor in 2025, it’s this: he is never going to say ‘no' to Bitcoin (BTC). Saylor’s firm, Strategy (Nasdaq: MSTR),…
Trump Is Promising That the U.S. Will Return to the Moon. Does That Really Make Little-Known SIDU Stock a Buy?
Trump’s renewed push for a U.S. return to the Moon has lifted space stocks like Sidus Space, but should you chase the rally?
White House Insider Buck Sexton: “Trump's Next Move Will Shock the World” It cou
dramatically increase U.S. power… and trigger a massive American market boom the likes of which we haven't seen in 75 years. Get the details here now.
💰 Investment Opportunities
Today’s News in a Nutshell
KATHMANDU: Khabarhub brings you a glimpse of major developments of the day in Nepal, including politics, business/economy, sports, entertainment, and more. Govt. holding election to establish good governance: PM Karki Prime Minister Sushila Karki has shared t…
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibit…
Nutriband CEO Publishes Letter to Shareholders
Nutriband New Year Letter to Shareholders…
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a…
Retail investors close out one of their best years ever. How they beat Wall Street at their own game
Mom-and-pop investors bought the dip at key points, giving them outsized benefits from the market's run this year.
One specific coin aligns perfectly with Trump's regulatory reforms and vision for America's financial dominance in the digital age.
Get the name of the ideal crypto for Trump's presidency for just $3 before his policies drive prices higher.
Market Commentary
Everyone’s ignoring how quickly pricing pressures could erode margins in weight-loss drugs. Novo Nordisk’s fortress looked unassailable until whispers of generics and price wars started swirling—this mismatch in sentiment is ripe for a nasty squeeze.
Consider how Vanda’s 18% FDA pop contrasts with slipping confidence in other small-caps: regulatory euphoria in one corner deepens unease elsewhere. Mesoblast’s board shake-up only adds fuel to M&A rumors, while Axsome’s Pre-NDA optimism hints at post-filing fireworks.
Actionable take-away: nibble on underowned names ahead of key FDA dates and trade policy catalysts around space funding. If that lunar plan gains traction, defense contractors and satellite plays could explode higher—don’t wait for the crowd.